VEGFA and age-related macular degeneration: Since the intravitreal injection of the anti-vascular endothelial growth factor (VEGF) agent, ranibizumab (IVR) (Lucentis®, Genentech Inc., South San Francisco, CA, USA), was approved for NV-AMD, the first-choice treatment for NV-AMD has been anti-VEGF therapies [10].